FDA Funding Discrepancy Relative To NIH Growth Attracts Hill Scrutiny
This article was originally published in The Gray Sheet
Executive Summary
FDA's belief that NIH budget doubling efforts justify corresponding increases to fund product reviews may be generating support among legislators.